Literature DB >> 18983875

Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.

Pramod Kumar1, Ravinder K Kaundal, Sandeep More, Shyam S Sharma.   

Abstract

The present study was carried out to elucidate the beneficial effect of pioglitazone in cognitive impairment induced by bilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in substantia nigra pars compacta (SNc) in rats, a model of Parkinson's disease. MPTP-lesioned rats showed poor cognitive performance in both passive avoidance task and cued version of the Morris water maze test. This deficit in learning and memory was found to be associated with oxidative stress. Chronic administration of pioglitazone (10 and 30 mg/kg, p.o., starting 5 days prior to MPTP administration and then for next 30 days) in MPTP-lesioned rats improved cognitive performance in passive avoidance task and cued version of the Morris water maze test. Furthermore, pioglitazone treatment also reduced oxidative stress (as evident by reduced malondialdehyde and increased glutathione levels). These results demonstrate the beneficial effects of pioglitazone on cognitive impairment in MPTP induced Parkinson's disease in rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983875     DOI: 10.1016/j.bbr.2008.10.010

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  34 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

2.  Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.

Authors:  Tristano Pancani; Jeremiah T Phelps; James L Searcy; Michael W Kilgore; Kuey-Chu Chen; Nada M Porter; Olivier Thibault
Journal:  J Neurochem       Date:  2009-05-11       Impact factor: 5.372

3.  Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.

Authors:  Chieh-Hsiang Lu; Chen-Yi Yang; Chung-Yi Li; Cheng-Yang Hsieh; Huang-Tz Ou
Journal:  Diabetologia       Date:  2017-11-14       Impact factor: 10.122

4.  Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task.

Authors:  Mariza Bortolanza; Evellyn C Wietzikoski; Suelen L Boschen; Patricia A Dombrowski; Mary Latimer; Duncan A A Maclaren; Philip Winn; Claudio Da Cunha
Journal:  Neurobiol Learn Mem       Date:  2010-06-01       Impact factor: 2.877

5.  Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Authors:  Jennifer R Schroeder; Karran A Phillips; David H Epstein; Michelle L Jobes; Melody A Furnari; Ashley P Kennedy; Markus Heilig; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2018-08-06       Impact factor: 4.530

Review 6.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

7.  Amelioration of diabetes-induced cognitive deficits by GSK-3β inhibition is attributed to modulation of neurotransmitters and neuroinflammation.

Authors:  Ashok Kumar Datusalia; Shyam Sunder Sharma
Journal:  Mol Neurobiol       Date:  2014-01-14       Impact factor: 5.590

8.  Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Lacey Pflibsen; Katherine A Stang; Michelle D Sconce; Vanessa B Wilson; Rebecca L Hood; Charles K Meshul; Suzanne H Mitchell
Journal:  J Neurosci Res       Date:  2015-08-31       Impact factor: 4.164

Review 9.  Nuclear receptors in neurodegenerative diseases.

Authors:  Rebecca Skerrett; Tarja Malm; Gary Landreth
Journal:  Neurobiol Dis       Date:  2014-05-27       Impact factor: 5.996

10.  Behavioral paradigms to evaluate PPAR modulation in animal models of brain injury.

Authors:  Dana Greene-Schloesser; Caroline I Schnegg; Mike E Robbins
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.